Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YHR1705 and YHR1706 Interaction in Healthy Volunteers
NCT03235362Phase 1Completed
- Sponsor
- Yuhan
- Start
- Aug 2017
- Primary completion
- Sep 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rosuvastatin and liquid metformin (Aspargo Labs) in dyslipidemia and type 2 diabetes mellitus (T2DM) (6 arms), sponsored by Yuhan. Primary endpoints: Area Under the Plasma Concentration-Time Curve at Steady State and Maximum Plasma Concentration at Steady State. Started Aug 2017; status: completed.
02
Drugs
rosuvastatinliquid metformin (Aspargo Labs)
03
Conditions
dyslipidemiatype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03235362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235362.